Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

NCT04728347 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
65
Enrollment
INDUSTRY
Sponsor class

Stopped A decision was made to terminate the study for operational/business reasons. This study was not terminated for reasons of safety or immunogenicity.

Conditions

Interventions

Sponsor

Arcturus Therapeutics, Inc.